{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T06:06:18Z","timestamp":1784700378764,"version":"3.55.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Autoantibodies against type I interferons (IFNs), particularly IFN-\u03b12 and IFN-\u03c9, are a recognized risk factor for severe COVID-19. Their functional characterization has largely focused on their neutralizing capacity. However, antibody binding avidity represents a distinct biophysical parameter that may be physiopathologically relevant. Whether avidity contributes to clinical outcomes in patient cohorts has not been evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We characterized the avidity of IgG autoantibodies against IFN-\u03b12 and IFN-\u03c9 by urea-dissociation ELISA in 95 patients with severe COVID-19 and confirmed anti-type I IFN autoantibodies. Avidity was classified as high (avidity index &amp;gt; 0.6) or low (avidity index \u2264 0.6). Clinical outcomes were compared between avidity groups, and patients were additionally stratified by combined avidity and neutralization profiles. Concordance between antibody subtypes was assessed by Cohen\u2019s kappa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 95 patients, 75 were positive for anti-IFN-\u03b12 autoantibodies (51 high, 24 low avidity) and 49 for anti-IFN-\u03c9 autoantibodies (31 high, 18 low avidity). Low anti-IFN-\u03b12 avidity was significantly associated with neurological complications (6\/24 [25%] vs. 3\/51 [6%]; OR 0.21 [0.05\u20130.84]; p = 0.026). For anti-IFN-\u03c9, a non-significant trend in the same direction was observed (3\/18 [17%] vs. 2\/31 [6%]; p = 0.342). Avidity and neutralizing capacity were related but not interchangeable, with a low positive predictive value of avidity for neutralization (47% for anti-IFN-\u03b12, 16% for anti-IFN-\u03c9). Stratification by the combined avidity\/neutralization phenotype identified the low-avidity + non-neutralizing combination of anti-IFN-\u03b12 autoantibodies as the subgroup with the highest neurological complication rate (6\/18 [33%]). Concordance between anti-IFN-\u03b12 and anti-IFN-\u03c9 avidity was modest (Cohen\u2019s \u03ba = 0.24; 62% concordant).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Antibody avidity is a functional characteristic of anti-type I IFN autoantibodies associated with neurological complications in severe COVID-19. In our cohort, avidity and neutralizing capacity are related but not equivalent, as a substantial proportion of high-avidity antibodies lack neutralizing activity, and the modest concordance between subtypes further suggests that these two autoantibody responses are partially independent. The combined assessment of avidity and neutralization identifies patients at higher neurological risk than either parameter alone, supporting avidity as an additional informative parameter in the functional characterization of anti-type I IFN autoantibodies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1893615","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:52:05Z","timestamp":1784699525000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Avidity of autoantibodies against type I interferons as a factor associated with neurological complications in severe COVID-19"],"prefix":"10.3389","volume":"17","author":[{"given":"Mario","family":"Framil","sequence":"first","affiliation":[{"name":"Immunology Department, Centre Diagn\u00f2stic Biom\u00e8dic, Hospital Cl\u00ednic de Barcelona","place":["Barcelona, Spain"]},{"name":"Universitat de Barcelona","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Garc\u00eda-Serrano","sequence":"additional","affiliation":[{"name":"Universitat de Barcelona","place":["Barcelona, Spain"]},{"name":"Immunology Department, Hospital Universitari de Bellvitge","place":["L\u2019Hospitalet de Llobregat, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e1n","family":"Garc\u00eda-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Immunology Department, Hospital Universitari de Bellvitge","place":["L\u2019Hospitalet de Llobregat, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"Caballero-Segarra","sequence":"additional","affiliation":[{"name":"Immunology Department, Hospital Universitari de Bellvitge","place":["L\u2019Hospitalet de Llobregat, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Gomez-Vazquez","sequence":"additional","affiliation":[{"name":"Universitat de Barcelona","place":["Barcelona, Spain"]},{"name":"Bellvitge Biomedical Research Institute (IDIBELL)","place":["L\u2019Hospitalet de Llobregat, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnau","family":"Antol\u00ed","sequence":"additional","affiliation":[{"name":"Universitat de Barcelona","place":["Barcelona, Spain"]},{"name":"Bellvitge Biomedical Research Institute (IDIBELL)","place":["L\u2019Hospitalet de Llobregat, Spain"]},{"name":"Internal Medicine Department, Hospital Universitari de Bellvitge","place":["L\u2019Hospitalet de Llobregat, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Solanich","sequence":"additional","affiliation":[{"name":"Universitat de Barcelona","place":["Barcelona, Spain"]},{"name":"Bellvitge Biomedical Research Institute (IDIBELL)","place":["L\u2019Hospitalet de Llobregat, Spain"]},{"name":"Internal Medicine Department, Hospital Universitari de Bellvitge","place":["L\u2019Hospitalet de Llobregat, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/imr.13304","article-title":"Human autoantibodies neutralizing type I IFNs: From 1981 to 2023","volume":"322","author":"Bastard","year":"2024","journal-title":"Immunol Rev"},{"key":"B3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032713-120231","article-title":"Interferon-stimulated genes: a complex web of host defenses","volume":"32","author":"Schneider","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.025","article-title":"Shared and distinct functions of type I and type III interferons","volume":"50","author":"Lazear","year":"2019","journal-title":"Immunity"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abl4340","article-title":"Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths","volume":"6","author":"Bastard","year":"2021","journal-title":"Sci Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20211387","article-title":"Human autoantibodies underlying infectious diseases","volume":"219","author":"Puel","year":"2022","journal-title":"J Exp Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1172\/jci166283","article-title":"Unlocking life-threatening COVID-19 through two types of inborn errors of type I IFNs","volume":"133","author":"Casanova","year":"2023","journal-title":"J Clin Invest"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd4570","article-title":"Inborn errors of type I IFN immunity in patients with life-threatening COVID-19","volume":"370","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-021-01136-x","article-title":"Pre-existing autoantibodies neutralizing high concentrations of type I interferons in almost 10% of COVID-19 patients admitted to intensive care in Barcelona","volume":"41","author":"Solanich","year":"2021","journal-title":"J ClinImmunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20202486","article-title":"Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine","volume":"218","author":"Bastard","year":"2021","journal-title":"J Exp Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20220514","article-title":"Autoantibodies against type I IFNs in patients with critical influenza pneumonia","volume":"219","author":"Zhang","year":"2022","journal-title":"J Exp Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20230661","article-title":"Autoantibodies neutralizing type I IFNs underlie West Nile virus encephalitis in approximately 40% of patients","volume":"220","author":"Gervais","year":"2023","journal-title":"J Exp Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2200413119","article-title":"The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodies","volume":"119","author":"Manry","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abh2624","article-title":"Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19","volume":"13","author":"van der Wijst","year":"2021","journal-title":"Sci Transl Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/art.39607","article-title":"Distinct functions of autoantibodies against interferon in systemic lupus erythematosus","volume":"68","author":"Gupta","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100894","article-title":"Inactive disease in patients with lupus is linked to autoantibodies to type I interferons that normalize blood IFN\u03b1 and B-cell subsets","volume":"4","author":"Bradford","year":"2023","journal-title":"Cell Rep Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1556731","article-title":"Non-neutralizing anti-type I interferon autoantibodies could increase thrombotic risk in critical COVID-19 patients","volume":"16","author":"Framil","year":"2025","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/159.4.736","article-title":"Recent primary toxoplasma infection indicated by a low avidity of specific IgG","volume":"159","author":"Hedman","year":"1989","journal-title":"J Infect Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/167.3.691","article-title":"Toxoplasmosis acquired during pregnancy: improved serodiagnosis based on avidity of IgG","volume":"167","author":"Lappalainen","year":"1993","journal-title":"J Infect Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26863","article-title":"The challenge of avidity determination in SARS-CoV-2 serology","volume":"93","author":"Bauer","year":"2021","journal-title":"J Med Virol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20242039","article-title":"Type I interferon autoantibody footprints reveal neutralizing mechanisms and allow inhibitory decoy design","volume":"222","author":"Groen","year":"2025","journal-title":"J Exp Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1127","article-title":"Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China","volume":"77","author":"Mao","year":"2020","journal-title":"JAMA Neurol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000009937","article-title":"Neurologic manifestations in hospitalized patients with COVID-19: the ALBACOVID registry","volume":"95","author":"Romero-S\u00e1nchez","year":"2020","journal-title":"Neurology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/nejmc2008597","article-title":"Neurologic features in severe SARS-CoV-2 infection","volume":"382","author":"Helms","year":"2020","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/s2215-0366(20)30287-x","article-title":"Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study","volume":"7","author":"Varatharaj","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"B27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2021.01.007","article-title":"Inflammatory leptomeningeal cytokines mediate COVID-19 neurologic symptoms in cancer patients","volume":"39","author":"Remsik","year":"2021","journal-title":"Cancer Cell"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00633-9","article-title":"The type I interferonopathies: 10 years on","volume":"22","author":"Crow","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00263-1","article-title":"CNS disease associated with enhanced type I interferon signalling","volume":"23","author":"Crow","year":"2024","journal-title":"Lancet Neurol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"110491","DOI":"10.1016\/j.clim.2025.110491","article-title":"Autoantibodies neutralizing type I interferons remain a significant risk factor for critical COVID-19 pneumonia in vaccinated patients","volume":"276","author":"Antol\u00ed","year":"2025","journal-title":"Clin Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1128\/cvi.00487-14","article-title":"Role of cytomegalovirus (CMV) IgG avidity testing in diagnosing primary CMV infection during pregnancy","volume":"21","author":"Prince","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1586\/14760584.2016.1128831","article-title":"How to assess the binding strength of antibodies elicited by vaccination against HIV and other viruses","volume":"15","author":"Klasse","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab1002","article-title":"Temporal dynamics of anti-type I interferon autoantibodies in patients with coronavirus disease 2019","volume":"75","author":"Shaw","year":"2022","journal-title":"Clin Infect Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0149154","article-title":"A generic mechanism for enhanced cytokine signaling via cytokine-neutralizing antibodies","volume":"11","author":"Shulgin","year":"2016","journal-title":"PloS One"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-715987","article-title":"Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature","volume":"128","author":"Kavanagh","year":"2016","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1893615\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:52:06Z","timestamp":1784699526000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1893615\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":35,"alternative-id":["10.3389\/fimmu.2026.1893615"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1893615","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"1893615"}}